OBJECTIVE: The purpose of this study was to examine the relationship of glycemic control and exogenous and endogenous insulin levels with all-cause and cause-specific mortality (ischemic heart disease and stroke) in an older-onset diabetic population. RESEARCH DESIGN AND METHODS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) is an ongoing, prospective, population-based cohort study of individuals with diabetes first examined in 1980-1982. A stratified sample of all individuals with diabetes diagnosed at 30 years of age or older was labeled "older-onset" (n = 1,370). Those participating in the 1984-1986 examination phase (n = 1,007) were included in the analysis. Endogenous insulin was determined by measurements of plasma C-peptide (in nanomoles per liter), and exogenous insulin was calculated in units per kilogram per day. Glycemic control was determined by levels of glycosylated hemoglobin (HbA(1)). RESULTS: After 16 years of follow-up, 824 individuals died (all-cause mortality); 358 deaths involved ischemic heart disease and 137 involved stroke. C-peptide and HbA(1) were significantly associated with all-cause and ischemic heart disease mortality in our study. The hazard ratio (95% CI) values for all-cause mortality were 1.12 (1.07-1.17) per 1% increase in HbA(1), 1.20 (0.85-1.69) per 1 unit x kg(-1) x day(-1) increase in exogenous insulin, and 1.15 (1.04-1.29) per 1 nmol/l increase in C-peptide and for ischemic heart disease mortality were 1.14 (1.06-1.22), 1.50 (0.92-2.46), and 1.19 (1.02-1.39) for HbA(1), exogenous insulin, and C-peptide, respectively, after adjusting for relevant confounders. C-peptide was associated with stroke mortality only among men (1.65 [1.07-2.53]). CONCLUSIONS: Our results show that individuals with higher endogenous insulin levels are at higher risk of all-cause, ischemic heart disease, and stroke mortality.
OBJECTIVE: The purpose of this study was to examine the relationship of glycemic control and exogenous and endogenous insulin levels with all-cause and cause-specific mortality (ischemic heart disease and stroke) in an older-onset diabetic population. RESEARCH DESIGN AND METHODS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) is an ongoing, prospective, population-based cohort study of individuals with diabetes first examined in 1980-1982. A stratified sample of all individuals with diabetes diagnosed at 30 years of age or older was labeled "older-onset" (n = 1,370). Those participating in the 1984-1986 examination phase (n = 1,007) were included in the analysis. Endogenous insulin was determined by measurements of plasma C-peptide (in nanomoles per liter), and exogenous insulin was calculated in units per kilogram per day. Glycemic control was determined by levels of glycosylated hemoglobin (HbA(1)). RESULTS: After 16 years of follow-up, 824 individuals died (all-cause mortality); 358 deaths involved ischemic heart disease and 137 involved stroke. C-peptide and HbA(1) were significantly associated with all-cause and ischemic heart disease mortality in our study. The hazard ratio (95% CI) values for all-cause mortality were 1.12 (1.07-1.17) per 1% increase in HbA(1), 1.20 (0.85-1.69) per 1 unit x kg(-1) x day(-1) increase in exogenous insulin, and 1.15 (1.04-1.29) per 1 nmol/l increase in C-peptide and for ischemic heart disease mortality were 1.14 (1.06-1.22), 1.50 (0.92-2.46), and 1.19 (1.02-1.39) for HbA(1), exogenous insulin, and C-peptide, respectively, after adjusting for relevant confounders. C-peptide was associated with stroke mortality only among men (1.65 [1.07-2.53]). CONCLUSIONS: Our results show that individuals with higher endogenous insulin levels are at higher risk of all-cause, ischemic heart disease, and stroke mortality.
Authors: A R Folsom; M L Rasmussen; L E Chambless; G Howard; L S Cooper; M I Schmidt; G Heiss Journal: Diabetes Care Date: 1999-07 Impact factor: 19.112
Authors: Marian J Muis; Michiel L Bots; Henk J G Bilo; Roel P L M Hoogma; Joost B L Hoekstra; Diederick E Grobbee; Ronald P Stolk Journal: Atherosclerosis Date: 2005-07 Impact factor: 5.162
Authors: Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington Journal: JCI Insight Date: 2019-02-26
Authors: Tahira Akbar; Stuart McGurnaghan; Colin N A Palmer; Shona J Livingstone; John Petrie; John Chalmers; Robert S Lindsay; John A McKnight; Donald W M Pearson; Alan W Patrick; James Walker; Helen C Looker; Helen M Colhoun Journal: Int J Epidemiol Date: 2017-06-01 Impact factor: 7.196
Authors: Vladimir Kron; Miroslav Verner; Ladislav Pesl; Pavel Smetana; Jaromir Kadlec; Daniel Martinik Journal: J Appl Biomed Date: 2021-10-13 Impact factor: 1.797
Authors: Yi Wan; Fred K Tabung; Dong Hoon Lee; Teresa T Fung; Walter C Willett; Edward L Giovannucci Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Federico Biscetti; Giuseppe Straface; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Paola Rizzo; Giulia De Angelis; Luigi Iuliano; Giovanni Ghirlanda; Andrea Flex Journal: Cardiovasc Diabetol Date: 2009-09-08 Impact factor: 9.951